RIGL Stock Analysis: Rigel Pharmaceuticals | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 899m USD | 12M Return: 62.3% | US7665597024 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 9.45M
Qual. Beats: 0
Rev. Trend: 94.8%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Rigel Pharmaceuticals is a U.S.-based biotechnology company that develops small-molecule therapies for hematologic disorders and cancer. It markets three approved products: TAVALISSE (fostamatinib) for chronic immune thrombocytopenia, REZLIDHIA (olutasidenib) for IDH1-mutated relapsed/refractory acute myeloid leukemia, and GAVRETO (pralsetinib) for RET fusion-positive non-small cell lung cancer and thyroid cancer. The company is also advancing R289, an oral IRAK1/4 inhibitor, into a Phase 1b study across hematology-oncology, autoimmune, and inflammatory indications, and has research collaborations with MD Anderson Cancer Center and the CONNECT network focused on IDH1-mutated cancers. Rigel is headquartered in South San Francisco and was incorporated in 1996.
The business model is typical of clinical-stage and commercial-stage biotechs: revenue is generated from a limited portfolio of approved drugs while a significant portion of capital is reinvested into pipeline R&D and clinical trials, exposing the company to regulatory and trial outcome risk. Small-molecule kinase inhibitors, which target specific cellular signaling pathways driving cancer and immune diseases, represent a major focus area within oncology drug development, and Rigels portfolio is concentrated in this class of targeted therapies.
- TAVALISSE and REZLIDHIA sales growth drives commercial revenue expansion
- R289 Phase 1b MDS data readout could lift pipeline valuation
- GAVRETO partnership royalties provide non-dilutive funding amid cash burn
| Net Income: 321.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.15 > 0.02 and ΔFCF/TA -16.59 > 1.0 |
| NWC/Revenue: 32.58% < 20% (prev 33.13%; Δ -0.55% < -1%) |
| CFO/TA 0.15 > 3% & CFO 79.4m > Net Income 321.9m |
| Net Debt (-54.7m) to EBITDA (94.0m): -0.58 < 3 |
| Current Ratio: 1.95 > 1.5 & < 3 |
| Outstanding Shares: last quarter (19.6m) vs 12m ago 7.75% < -2% |
| Gross Margin: 91.39% > 18% (prev 91.52%; Δ -0.13% > 0.5%) |
| Asset Turnover: 76.06% > 50% (prev 129.6%; Δ -53.54% > 0%) |
| Interest Coverage Ratio: 15.74 > 6 (EBIT TTM 91.4m / Interest Expense TTM 5.80m) |
| A: 0.17 (Total Current Assets 185.5m - Total Current Liabilities 95.4m) / Total Assets 521.1m |
| B: -1.91 (Retained Earnings -997.1m / Total Assets 521.1m) |
| C: 0.25 (EBIT TTM 91.4m / Avg Total Assets 363.9m) |
| D: 4.46 (Book Value of Equity 425.4m / Total Liabilities 95.4m) |
| Altman-Z'' = 1.27 = BB |
| DSRI: 1.36 (Receivables 56.0m/39.9m, Revenue 276.8m/267.9m) |
| GMI: 1.00 (GM 91.52% / 91.39%) |
| AQI: 4.41 (AQ_t 0.64 / AQ_t-1 0.15) |
| SGI: 1.03 (Revenue 276.8m / 267.9m) |
| TATA: 0.47 (NI 321.9m - CFO 79.4m) / TA 521.1m) |
| Beneish M = -0.63 (Cap -4..+1) = D |
As of November 02, 2026, the stock is trading at USD 51.31 with a total of 174,405 shares traded. Over the past week, the price has changed by +6.61%, over one month by +4.95%, over three months by +34.81% and over the past year by +62.27%.
Current recommended Stop Loss: 48.40 (which is 5.7% or 1.8 ATR below the current price).
Rigel Pharmaceuticals has received a consensus analysts rating of 4.20. Therefore, it is recommended to buy RIGL.
- StrongBuy: 3
- Buy: 0
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 63 | 22.8% |
P/E Trailing = 2.8513
P/E Forward = 9.2851
P/S = 3.2482
P/B = 2.1436
P/EG = -0.1
Revenue TTM = 276.8m USD
EBIT TTM = 91.4m USD
EBITDA TTM = 94.0m USD
Long Term Debt = 22.5m USD (from longTermDebt, last fiscal year)
Short Term Debt = 39.9m USD (from shortTermDebt, last quarter)
Debt = 40.7m USD (from shortLongTermDebtTotal, last quarter) + Leases 714k
Net Debt = -54.7m USD (calculated: Debt 40.7m - CCE 95.3m)
Enterprise Value = 844.4m USD (899.1m + Debt 40.7m - CCE 95.3m)
Interest Coverage Ratio = 15.74 (Ebit TTM 91.4m / Interest Expense TTM 5.80m)
EV/FCF = 10.64x (Enterprise Value 844.4m / FCF TTM 79.4m)
FCF Yield = 9.40% (FCF TTM 79.4m / Enterprise Value 844.4m)
FCF Margin = 28.68% (FCF TTM 79.4m / Revenue TTM 276.8m)
Net Margin = 116.3% (Net Income TTM 321.9m / Revenue TTM 276.8m)
Gross Margin = 91.39% ((Revenue TTM 276.8m - Cost of Revenue TTM 23.8m) / Revenue TTM)
Gross Margin QoQ = 89.17% (prev 92.17%)
Tobins Q-Ratio = 1.62 (Enterprise Value 844.4m / Total Assets 521.1m)
Interest Expense / Debt = 14.28% (Interest Expense 5.80m / Debt 40.7m)
Taxrate = 26.69% (6.29m / 23.6m)
NOPAT = 67.0m (EBIT 91.4m * (1 - 26.69%))
Current Ratio = 1.95 (Total Current Assets 185.5m / Total Current Liabilities 95.4m)
Debt / Equity = 0.10 (Debt 40.7m / totalStockholderEquity, last quarter 425.4m)
Debt / EBITDA = -0.58 (Net Debt -54.7m / EBITDA 94.0m)
Debt / FCF = -0.69 (Net Debt -54.7m / FCF TTM 79.4m)
Total Stockholder Equity = 333.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 88.46% (Net Income 321.9m / Total Assets 521.1m)
RoE = 96.49% (Net Income TTM 321.9m / Total Stockholder Equity 333.6m)
RoCE = 25.66% (EBIT 91.4m / Capital Employed (Equity 333.6m + L.T.Debt 22.5m))
RoIC = 14.83% (NOPAT 67.0m / Invested Capital 451.8m)
WACC = 8.97% (E(899.1m)/V(939.7m) * Re(8.90%) + D(40.7m)/V(939.7m) * Rd(14.28%) * (1-Tc(0.27)))
Discount Rate = 8.90% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.36 | Cagr: 5.04%
[DCF] Terminal Value 75.99% ; FCFF base≈73.9m ; Y1≈84.8m ; Y5≈124.8m
[DCF] Fair Price = 93.58 (EV 1.69b - Net Debt -54.7m = Equity 1.75b / Shares 18.7m; r=8.97% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.04 | # QB: 0
Revenue Correlation: 94.76 | Revenue CAGR: 48.83% | SUE: 2.28 | # QB: 1
EPS current Quarter (2026-09-30): EPS=0.96 | Chg30d=+0.00% | Revisions=-57% | Analysts=4
EPS current Year (2026-12-31): EPS=3.54 | Chg30d=+0.00% | Revisions=-29% | GrowthEPS=-44.9% | GrowthRev=+3.9%
EPS next Year (2027-12-31): EPS=4.94 | Chg30d=+0.00% | Revisions=+0% | GrowthEPS=+39.4% | GrowthRev=+21.9%
[Analyst] Revisions Ratio: -40% (up=3, down=9)